Pseudovirus

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) has spread widely around the world. The full spectrum of COVID-19 ranges from mild, self-limiting respiratory diseases to severe progressive pneumonia, multiorgan failure, and death. What's more, because the SARS-CoV-2 is highly contagious and asymptomatic, its transmission is more difficult to control. As a leading company, Creative Biolabs is actively taking action to provide reliable and high-quality pseudovirus products and customized services for SARS-CoV-2 research, and assists our customers in the development of vaccines or treatments for SARS-CoV-2 infection.

Introduction of SARS-CoV-2

SARS-CoV-2 is an enveloped, non-segmented, positive-sense RNA virus that is widely distributed in humans and other mammals and belongs to the sarbecovirus subfamily. It is about 65-125 nm in diameter, contains single-stranded RNA, and has a coronal protrusion on its outer surface. Among them, the glycosylated spike (S) protein is the major surface protein of SARS-CoV-2, responsible for receptor binding and fusion of viral membrane and cell membrane. It is one of the key components that bind receptors and mediate membrane fusion and virus entry. Therefore, S protein is the main goal of neutralizing antibody and vaccine design.

Structure and genome of SARS-CoV-2.Fig.1 Structure and genome of SARS-CoV-2. (Astuti, 2020)

Why Need Pseudovirus?

Due to its high infectivity and pathogenicity, SARS-CoV-2 research should be handled in the Biosafety Level (BSL)-3 laboratory, which limits the development of antiviral measures. Pseudoviruses are considered to be safe and effective virological tools, especially for emerging and re-emerging viruses, because they have the basic components of cell entry and virus infection, but lack of nucleic acid and lose the ability of self-replication. Therefore, using the SARS-CoV-2 S protein as a prototype and designing pseudoviruses to mimic the SARS-CoV-2 virus for further research is the choice advocated by many researchers. With extensive experience in pseudoviruses, Creative Biolabs provides pseudovirus services based on lentivirus (LV) and vesicular stomatitis virus (VSV) systems for SARS-CoV-2 S protein.

  • LV vector packaging systems

Because of their high efficiency, LV vectors are often the first choice for packaging systems to produce encapsulated pseudoviruses. These vectors are mainly from human immunodeficiency virus (HIV-1), simian immunodeficiency virus (SIV) or feline immunodeficiency virus (FIV).

  • VSV vector packaging systems

VSV vector packaging system is a general tool for producing pseudotype virus. The advantage of this system is that it has no strict selectivity for envelope protein, and the resulting virus can be operated in the BSL-2 laboratory.

At present, we offer the following pseudovirus products for SARS-CoV-2 S protein:

  • SARS-CoV2-S-PseudoVSV-mCherry
  • SARS-CoV2-S-PseudoVSV-EGFP
  • SARS-CoV2-S-PseudoVSV-Luc
  • SARS-CoV2-S-PseudoLV-mCherry
  • SARS-CoV2-S-PseudoLV-EGFP
  • SARS-CoV2-S-PseudoLV-Luc

In addition, if there is no product you need in our product list, we can customize the pseudovirus according to your needs.

Why Choose Us?

  • With a mature and excellent platform and years of pseudovirus experience, we have the ability to provide you with the best quality products and services with the highest efficiency;
  • For special product requirements, we have a one-stop customized pseudovirus production capacity;
  • Competitive price and best after-sales service.

Together with researchers and scientists around the world, Creative Biolabs is committed to providing high-quality pseudovirus services for SARS-CoV-2 research and contributing to the global pandemic of COVID-19.

Reference

  1. Astuti, I. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2020(14): 407-412.

For research use only. Not intended for any clinical use.